| |
Article Title |
Author(s) |
Type |
Pages |
|
Featuring the special issue editors Olaf Witt and Ralph Lindemann
8 August 2009 (Vol. 280 | No. 2 | Pages 121-122)
|
|
Publisher’s note
|
121-122
|
|
HDAC inhibitors: Magic bullets, dirty drugs or just another targeted therapy
8 August 2009 (Vol. 280 | No. 2 | Pages 123-124)
|
Olaf Witt,
Ralph Lindemann
|
Editorial
|
123-124
|
|
Enhancing the apoptotic and therapeutic effects of HDAC inhibitors
8 August 2009 (Vol. 280 | No. 2 | Pages 125-133)
|
Ailsa J. Frew,
Ricky W. Johnstone,
Jessica E. Bolden
|
Short survey
|
125-133
|
|
Histone deacetylase inhibitors as a new weapon in the arsenal of differentiation therapies of cancer
8 August 2009 (Vol. 280 | No. 2 | Pages 134-144)
|
Oronza Antonietta Botrugno,
Fabio Santoro,
Saverio Minucci
|
Short survey
|
134-144
|
|
Targeting tumor angiogenesis with histone deacetylase inhibitors
8 August 2009 (Vol. 280 | No. 2 | Pages 145-153)
|
Leigh Ellis,
Hans Hammers,
Roberto Pili
|
Short survey
|
145-153
|
|
HDAC inhibitors in models of inflammation-related tumorigenesis
8 August 2009 (Vol. 280 | No. 2 | Pages 154-159)
|
Rainer Glauben,
Elena Sonnenberg,
Martin Zeitz,
Britta Siegmund
|
Short survey
|
154-159
|
|
HDACi – Targets beyond chromatin
8 August 2009 (Vol. 280 | No. 2 | Pages 160-167)
|
Marc Buchwald,
Oliver H. Krämer,
Thorsten Heinzel
|
Short survey
|
160-167
|
|
HDAC expression and clinical prognosis in human malignancies
8 August 2009 (Vol. 280 | No. 2 | Pages 168-176)
|
Wilko Weichert
|
Short survey
|
168-176
|
|
Biomarkers for predicting clinical responses to HDAC inhibitors
8 August 2009 (Vol. 280 | No. 2 | Pages 177-183)
|
Lindsay Stimson,
Nicholas B. La Thangue
|
Short survey
|
177-183
|
|
Histone deacetylase inhibitor induced modulation of anti-estrogen therapy
8 August 2009 (Vol. 280 | No. 2 | Pages 184-191)
|
Scott Thomas,
Pamela N. Munster
|
Short survey
|
184-191
|
|
Histone deacetylase inhibitors as anti-neoplastic agents
8 August 2009 (Vol. 280 | No. 2 | Pages 192-200)
|
Nicolas Batty,
Gabriel G. Malouf,
Jean Pierre J. Issa
|
Short survey
|
192-200
|
|
Development of vorinostat: Current applications and future perspectives for cancer therapy
8 August 2009 (Vol. 280 | No. 2 | Pages 201-210)
|
Victoria M. Richon,
Jose Garcia-Vargas,
James S. Hardwick
|
Short survey
|
201-210
|
|
Isoform-specific histone deacetylase inhibitors: The next step?
8 August 2009 (Vol. 280 | No. 2 | Pages 211-221)
|
Sriram Balasubramanian,
Erik Verner,
Joseph J. Buggy
|
Short survey
|
211-221
|
|
Histone deacetylase inhibitors that target tubulin
8 August 2009 (Vol. 280 | No. 2 | Pages 222-232)
|
Jörg Schemies,
Wolfgang Sippl,
Manfred Jung
|
Short survey
|
222-232
|
|
Development of the pan-DAC inhibitor panobinostat (LBH589): Successes and challenges
8 August 2009 (Vol. 280 | No. 2 | Pages 233-241)
|
Peter Atadja
|
Short survey
|
233-241
|
